Stimuli-Responsive Calcium Phosphate Nanoreactor for Synergistic Chemo-Photothermal-Ferroptosis Therapy of Colorectal Cancer Authors: Xinxin Zhang, Fengyuan Qian, Yixiang Huang, Bowen Zheng, Ziran Wang, Huanhuan Zhu, Bo Zhang Published: 2026 ABSTRACT AbstractBackgroundColorectal cancer therapy encounters major obstacles, including insufficient tumor targeting, systemic toxicity, and the emergence of drug resistance, underscoring the need for advanced therapeutic modalities. This work aimed to engineer a multi-mechanism synergistic nanoplatform to surmount these limitations.MethodsA hyaluronic acid–modified calcium phosphate nanoparticle construct (CaPHDH) was developed incorporating a dual-action mechanism via calcium ion chelation and hydrophobic entrapment. Hemin was encapsulated within the calcium phosphate lattice via a green synthesis approach, followed by electrostatic loading of doxorubicin (DOX). The nanoparticles were comprehensively characterized for physicochemical properties. Antitumor efficacy was assessed in vitro in CT26 colorectal carcinoma cells and in vivo in a CT26 tumor-bearing murine model, with or without 808 nm laser irradiation. Mechanistic investigations, including ferroptosis and immune activation, were conducted.ResultsThe CaPHDH nanoparticles exhibited a uniform size of approximately 100 nm, excellent dispersibility, pH-triggered drug release, and high photothermal conversion efficiency. In vitro, treatment produced a markedly enhanced anti-tumor effect against CT26 cells under 808 nm laser irradiation, attributable to the synergistic actions of chemotherapy, photothermal therapy, and ferroptosis induction. In vivo, CaPHDH achieved effective tumor-specific accumulation and, upon laser irradiation, yielded superior tumor growth inhibition relative to monotherapies. In addition, CaPHDH treatment significantly promotes the polarization of tumor-associated macrophages (TAMs) toward the M1 phenotype, thereby reshaping the tumor immune microenvironment. Comprehensive biosafety assessments indicated no significant systemic toxicity, organ damage, or abnormal alterations in standard blood biochemical parameters.ConclusionThis study successfully developed a biosafety-optimized nanodelivery platform, CaPHDH, which integrates chemotherapy, photothermal therapy, and ferrocide induction. This platform enables highly effective synergistic treatment in a mouse rectal cancer model, offering new insights into combination therapy strategies for tumors.Keywords: colorectal cancer, calcium phosphate nanoparticles, hyaluronic acid, photothermal therapy, ferroptosis, drug delivery Introduction Colorectal cancer (CRC) ranks among the leading causes of cancer incidence and mortality worldwide, and its clinical management continues to pose significant challenges.1,2 Early-stage CRC can achieve a favorable prognosis through curative surgery; however, approximately 20% of patients present with distant metastases at initial diagnosis, and another 25% of patients with localized disease eventually progress to metastatic cancer.3 Current traditional treatment strategies, centered on surgery, chemotherapy, and radiation therapy, are limited by severe systemic adverse effects, a lack of therapeutic selectivity, and inherent or acquired multidrug resistance, resulting in suboptimal overall efficacy; survival benefits for patients with metastatic disease are particularly limited.4,5 In recent years, rapid advancements in nanotechnology have opened new avenues for cancer treatment. By designing intelligent nanomedicine delivery systems, it is possible to achieve specific accumulation and controlled release of drugs at tumor sites, thereby enhancing therapeutic efficacy while significantly reducing systemic toxicity.6–9 Among various novel cancer treatment strategies, photothermal therapy (PTT) has garnered significant attention due to its minimally invasive nature, temporal and spatial controllability, and potential to eliminate drug-resistant cells.10–12 However, the efficacy of PTT heavily relies on efficient and safe photothermal converters. Although inorganic nanomaterials like gold,13,14 iron,15,16 copper17 and different carbon nanostructures nanoparticles,18,19 which are currently widely studied, exhibit good photothermal properties, their potential risks of long-term accumulation in the body, complex surface functionalization requirements, and instability under high-power laser irradiation severely limit their clinical translation prospects.20,21 Near-infrared (NIR)-absorbing organic small-molecule compounds such as porphyrins and porphyrin derivatives,22,23 quinone compounds/benzoquinones,24 etc., can generate heat upon photonic excitation. These compounds are characterized by ease of modification and derivatization, minimal side effects, and high photothermal conversion efficiency; therefore, they are considered promising candidates for effective photothermal agents. Hemin chloride, as an endogenous substance in the human body, exhibits unique advantages: it not only efficiently absorbs light energy and generates heat in the near-infrared region (808 nm), but the released Fe2⁺ can also catalyze the Fenton reaction, inducing ferroptosis in tumor cells25,26—a novel form of cell death that synergizes. This multifunctional integration of photothermal and chemokinetics therapies makes it an ideal core unit for constructing synergistic antitumor platforms. There has been very little research on the use of the hemin photothermal effect for treating tumors. Various inorganic nanocarriers, such as metal-organic frameworks (MOFs) coated with MnO2 nanosheets, have been used to co-deliver doxorubicin (DOX) and DNAzymes, enabling the synergistic delivery of chemotherapeutic agents and bioactive molecules to achieve antitumor effects characterized by enhanced efficacy and reduced toxicity.27 CaP NPs offer advantages such as good biocompatibility, degradability, and pH-responsive dissolution, making them an ideal drug delivery platform.28,29 The degradation products of CaP NPs nanoparticles (Ca2⁺ and PO43−) are endogenous components of the human body and can be safely metabolized; their amorphous structure confers the advantages of high drug-loading capacity and pH-responsive release.30,31 Previous studies have designed ultrasonic-responsive calcium-copper phosphate nanomaterials (Ca19Cu2(PO4)14) to induce tumor cell death through the synergistic release of Cu2⁺ and Ca2⁺.32 Ferroptosis is an iron-dependent, lipid peroxidation-driven form of programmed cell death that is highly effective against tumor cells resistant to apoptosis; therefore, the targeted induction of ferroptosis has emerged as a new strategy for overcoming tumor resistance. Natural products such as shikonin can downregulate SLC7A11 and GPX4 via the ROS/JNK pathway, thereby inducing ferroptosis and inhibiting tumor proliferation, migration, and invasion.32,33 In this study, we developed a calcium phosphate (CaP)-based hyaluronic acid (HA)-targeted nanocomposite system (CaPHDH) for the combined delivery of chlorhexidine and doxorubicin (DOX) to achieve synergistic treatment of colorectal cancer. As shown in Scheme 1, a in situ coprecipitation/coassembly strategy was employed to encapsulate hemin within the CaP scaffold; DOX was loaded via electrostatic adsorption; and HA modification endowed the system with CD44 receptor-mediated targeting capability,34,35 In the acidic tumor microenvironment, CaPHDH responsively releases the drug: DOX induces DNA damage and a burst of ROS increase (blue arrows,36,37 under 808 nm laser irradiation, hemin mediates photothermal therapy while simultaneously releasing Fe2⁺ to catalyze the Fenton reaction,38,39 driving the accumulation of lipid peroxides(LPO) and depleting GSH, thereby blocking the SLC7A11-GSH-GPX4 axis, inactivating GPX4, and eliminating tumor cells. Furthermore, photothermal therapy and the ferroptosis process may induce the release of tumor-associated antigens and damage-associated molecular patterns (DAMPs), creating favorable conditions for combination immunotherapy. Schematic illustration of the preparation process and the mechanism of treatment for colorectal cancer of CaPHDH. (CaPH: CaPNPs@Hemin; CaPHD: CaPNPs@Hemin@DOX; CaPHDH: CaPNPs@Hemin@DOX@ Hyaluronic acid). An upward arrow (blue) indicates an increase in expression levels in the cells, and a downward arrow (red) indicates a decrease in expression levels. Materials and Methods Materials Calcium chloride was provided by Sangon Biotech. Sodium hyaluronate, doxorubicin hydrochloride, Rhodamine B, and DAPI were supplied by Aladdin Biotech. The lysozyme green DND-2 probe was provided by Shanghai Yesen Biotech. The GSH and GSSG Assay Kit and the Lipid Oxidation (MDA) Assay Kit were purchased from Beyotime Biotechnology. Cell culture medium, phosphate-buffered saline, 0.25% ferric chloride, penicillin/streptomycin (PS) solution, and sugar-free Dulbecco’s Modified Eagle Medium (DMEM) required for cell experiments were provided by Gibco. Synthesis of Hollow Calcium Phosphate Nanocarriers In this study, a green synthesis strategy based on biomineralization was employed to prepare hollow calcium phosphate (CaP NPs) nanocarriers. Specifically, 0.5 g of bovine serum albumin (BSA, purity ≥98%, Sigma-Aldrich) was dissolved in 50 mL of sugar-free DMEM medium and shaken at 37 °C and 120 rpm for 30 minutes to ensure complete dispersion of the BSA. Subsequently, 100 μL of a 1 mol/L aqueous solution of calcium chloride (CaCl2, analytical grade) was slowly added dropwise to the solution; after rapid mixing via vortexing, the mixture was left to incubate undisturbed in a 37 °C incubator for 24 h. After the reaction was complete, the precipitate was collected by centrifugation at 10,000 rpm and 4 °C for 10 minutes, then washed three times with deionized water and anhydrous ethanol, respectively, with the precipitate collected by centrifugation under the same conditions after each wash. Finally, the product was freeze-dried under vacuum overnight to yield white, powdery hollow calcium phosphate nanocarriers (CaP NPs), which were sealed and stored in a desiccator at 4 °C. Synthesis of CaPNPs@Hemin@DOX@ Hyaluronic Acid (CaPHDH) Synthesis of CaP@Hemin nanoparticles (CaPH): Accurately weigh 0.5 g of bovine serum albumin (BSA) and dissolve it in 50 mL of sugar-free DMEM medium. Incubate the mixture on a constant-temperature shaker at 37 °C and 120 rpm for 30 minutes to ensure that the BSA is fully dissolved and uniformly dispersed. Next, dissolve 3 mg of hemin chloride in an appropriate amount of dimethyl sulfoxide (DMSO) to prepare a hemin-DMSO solution, and slowly add it dropwise to the BSA solution while gently stirring to mix thoroughly. Next, 100 μL of a 1 mol/L aqueous calcium chloride (CaCl2) solution was added to the mixture; while adding the solution dropwise, it was rapidly mixed using a vortex mixer, and the mixture was then left to incubate undisturbed in a 37 °C incubator for 24 h to drive the mineralization reaction. After the reaction was complete, the product was centrifuged at 10,000 rpm for 10 min. The supernatant was discarded, and the precipitate was collected. It was washed three times with deionized water (centrifuged and collected under the same conditions after each wash), yielding hemin-loaded calcium phosphate nanoparticles (CaP@Hemin), which were stored at 4 °C for later use. Doxorubicin (DOX) Loading: The CaP@Hemin nanoparticles were redispersed in an aqueous DOX solution (concentration: 5 mg/mL) and stirred for 2 hours at room temperature under light-protected conditions to load DOX onto the nanoparticle surface via electrostatic adsorption. After loading was complete, the product was collected by centrifugation at 10,000 rpm for 10 minutes and washed three times with deionized water to remove unbound free DOX. The resulting nanoparticles were then redispersed in ultrapure water, sonicated for 5 minutes to promote uniform dispersion, and centrifuged. The final product is a calcium phosphate nanocomposite system loaded with hemin chloride and doxorubicin, named CaP@Hemin@DOX (abbreviated as CaPHD), which was stored at 4 °C away from light for future use. Synthesis of CaP@Hemin@DOX@HA nanoparticles (CaPHDH): The CaP@Hemin@DOX nanoparticles obtained as described above were redispersed in a 5 mg/mL aqueous solution of sodium hyaluronate (HA, molecular weight 10 kDa) and stirred under a magnetic stirrer at room temperature for 60 min to anchor HA to the nanoparticle surface via electrostatic adsorption or hydrogen bonding. After the reaction, the CaPHDH were collected by centrifugation at 10,000 rpm for 10 min and washed twice with deionized water to remove unbound free HA. The final product was CaPHDH nanoparticles. The CaP@Hemin@HA composite (CaPHH) was prepared using the same procedure described above; specifically, the CaP@Hemin nanoparticles were coated with sodium hyaluronate using the same method. Cell Culture and CCK-8 Test in CT26 Cell culture: The cell experiments were conducted using mouse colon cancer cells (CT26). The cells were purchased from the Chinese Academy of Sciences Cell Bank (Shanghai, China) in 2026. Since this source is not classified as an internationally accredited repository, the Institutional Research Ethics Committee of Shanghai Tenth People’s Hospital specifically reviewed the provenance and donor consent history of this cell line and formally approved its use in this study (Approval No. SHDSYY-2025-4622) and cells were cultured in a constant-temperature incubator (37°C, 95% air, 5% carbon dioxide) according to published literature. CT26 mouse tumor cells were cultured in 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin to maintain cell viability under routine culture conditions. Cell culture: After digestion and counting of CT26 cells in the logarithmic growth phase, cells were seeded at a density of 8,000 cells per well into a 96-well plate. Each well was then added 100μL of 1640 medium. The plate was incubated at 37°C in a 5% CO2 incubator for 24 hours to allow cells to adhere and grow. Drug Administration: Aspirate the original culture medium and add fresh 1640 containing different concentrations of CaP NPs, CaPHH, CaPHDH, and CaPHDH + L (100 μL per well), with 3 replicate wells per concentration and continue culturing for 24 hours. Cell Viability Assay: Add 10 μL of CCK-8 solution to each well. Gently shake to mix, then return to the incubator for 1 hours in 37°C environment. Then obtain the absorbance (OD value) of each well at 450 nm using a microplate reader and record the experimental results. Hemolysis Contrast Test A hemolysis test was employed to verify whether nanomedicines and red blood cells (RBCs) in a buffer solution would affect the hemolytic reaction of RBCs. The specific experiment was conducted as follows: 1 mL of fresh non-hemolyzed blood was obtained from mice, and the serum was removed by centrifugation (2000 rpm, 5 minutes). Then, 10 mL of PBS was added to resuspend the cell pellet, followed by gentle inversion up and down to mix evenly. Subsequent centrifugation was performed at a speed of 2000 revolutions per minute for 10 minutes, and finally the supernatant was discarded. Resuspend the cell pellet in PBS, then centrifuge to remove the supernatant so that all serum is eliminated. Disperse the obtained cell pellet in 12 mL of PBS. Then, aliquot the mixture into 10 test tubes, with 1 mL per tube. Add water (as the positive control) and PBS (as the negative control) to the control groups, and add (4–250 μg of the test substance) to the experimental group. Subsequently, place all samples in an incubator for 2 hours of incubation. Specifically, the positive group receives 1 mL of water, and the negative group receives 1 mL of PBS. After incubation, centrifuge the samples at 12,000 revolutions per minute for 10 minutes. Transfer the resulting supernatant to a 96-well plate in sequence, and measure and record the absorbance value at 570 nanometers. The hemolysis rate is calculated using the formula: Hemolysis Rate (%) = (Sample Value – Negative Control Value) / (Average Positive Control Value – Negative Control Value). Detection of Intracellular ATP Level To investigate whether CaPHDH affects mitochondria within tumor cells, we performed ATP assays on cells subjected to different treatments. Briefly, CT26 cells were digested and seeded at a density of 1×105 cells per well in a 12-well plate. After 24 hours of culture, cells were further cultured for 12 and 24 hours in medium containing either vehicle CaP NPs, CaPHH, or CaPHDH. Cells were then harvested, lysed, and the supernatant was collected. ATP levels were measured using an ATP bioluminescence assay kit. Detection of Lipid Peroxidation (MDA) and Reduced Glutathione (GSH) Briefly, CT26 cells were digested and seeded at a density of 1×106 cells per well in a 6-well plate. After 24 hours of culture, cells were further cultured for 12 and 24 hours in medium containing either vehicle CaP NPs, CaPHH, or CaPHDH and Fer-1+ CaPHDH. Cells were then harvested, lysed, and the supernatant was collected. MDA and GSH levels were measured using the GSH and GSSG Assay Kit and the Lipid Oxidation (MDA) Assay Kit. Measurement of the Photothermal Effect of CaPHDH in ddH2O To evaluate the photothermal efficacy of CaPHDH for photothermal therapy (PTT) in vitro, its aqueous phase photothermal effect was stimulated using near-infrared laser (wavelength 808 nm), followed by PTT experiments in mice. A 200 μL aliquot of CaPHDH solution was placed in a small EP tube at progressively increasing concentrations. Each sample was irradiated from the bottom with laser light at different powers for 10 minutes. Temperature changes and thermal imaging were monitored in real time using a photothermal imaging system, with data recorded every 30 seconds. Bio-Distribution and Analysis Fluorescence Imaging in Vivo The experimental protocol for this study was approved by the Animal Ethics Committee of Shanghai Tenth People’s Hospital. All animal experiments were conducted strictly in accordance with the Guidelines for the Care and Use of Laboratory Animals. The tumor model employed involved subcutaneous inoculation of 1×106 CT26 cells into 5-week-old male BABL/c. We employed CaPHDH @Rh B for in vitro fluorescence imaging, with excitation at 535 nm and emission at 600 nm. Fluorescence images were recorded at multiple time points (0, 30min, 1h, 2h, 8h, 24h, 48h) following tail vein injection of the nanoparticle solution into mice and subsequently analyzed. Measurement of Tumor Photothermal Effects Animal experiments were conducted at the SPF Animal Center of Shanghai Tenth People’s Hospital. The mice were housed in an environment with a 12-hour light/12-hour dark cycle and had free access to sterilized feed and sterilized drinking water. All male BALB/c mice (5 weeks old) were purchased from Shanghai Jihui Laboratory Animal Co., Ltd. A subcutaneous colon cancer xenograft model was established by injecting 100 μL of tumor cell suspension (1 × 106 CT26 cells) subcutaneously into the hind limbs of the mice. Once the tumors in the mice had grown to 0.3 cm3, photothermal experiments were conducted. In the in vitro photothermal therapy experiment, three groups of tumor-bearing mice (five mice per group) were administered CaPHDH, CaP NPs, and PBS via tail vein injection. Twelve hours later, the experimental group received near-infrared laser therapy (808 nm, 3.0 W cm−2, 10 min) to treat the tumors; simultaneously, a thermal imaging camera was used to monitor real-time temperature changes at the tumor site. Finally, the mice were euthanized. The specific method is as follows: the mice were anesthetized with isoflurane, followed by cervical dislocation. The bodies were placed in a refrigerator and disposed of in accordance with standard laboratory protocols. All animal experiments were performed in compliance with the guidelines approved by the Ethics Committee of Shanghai Tenth People’s Hospital (SHDSYY-2025-4622). The Measurement of Intracellular Reactive Oxygen Species Production Confocal imaging experiment: Well-grown CT26 cells were dispersed in DMEM (10 × 104 cells/mL), with 1 mL added to each confocal dish. The dishes were then placed in a cell culture incubator for 24 hours to allow cell attachment. Subsequently, CaP NPs, CaPHH, and CaPHDH nanoparticles for 12 hours. Cells were irradiated with an 808 nm laser (1 W/cm2) for 10 minutes. H2DCFDA (1 μg/mL) probe solution was added, and after incubation at 37°C for 30 minutes, fluorescence imaging was performed using laser confocal microscopy. Flow Cytometry ROS Detection: Dispersed well-growing CT26 cells in DMEM (10 × 104 cells/mL), added 1 mL to a 12-well cell culture plate, and placed in a cell culture incubator for 24 hours until cells adhered. Subsequently, CaP NPs, CaPHH, and CaPHDH nanoparticles for 12 hours. Irradiate cells with an 808 nm laser (1 W/cm2) for 10 minutes. Add H2DCFDA (1 μg/mL) probe solution and incubate at 37°C for 30 minutes. Discard supernatant, then digest cells with trypsin and disperse in PBS buffer. Data were analyzed and recorded using a BD flow cytometer. The Therapeutic Efficacy Study in Vivo Animal experiments were conducted at the SPF Animal Center of Shanghai Tenth People’s Hospital. All male BALB/c mice (5 weeks old) were purchased from Shanghai Jihui Laboratory Animal Co., Ltd. A subcutaneous colon cancer xenograft model was established by injecting 100 μL of tumor cell suspension (1×106 CT26 cells) subcutaneously into the hind limbs of the mice. Tumor-bearing mice were randomly divided into 8 groups, each receiving different drugs via tail vein injection and corresponding treatments. The specific groups were: PBS, PBS+Laser, CaP NPs, CaP NPs+Laser (CaP NPs+L), CaPHH, CaPHH+Laser (CaPHH+L), CaPHDH, and CaPHDH+Laser (CaPHDH+L) group. During the experiment, the photothermal therapy groups were irradiated at the tumor site with an 808 nm laser (3 W/cm2, 10 min); drug injection and laser irradiation were performed every 3 days. During treatment, the major and minor diameters of the tumors were measured every two days using a Vernier caliper (Volume = a2 × b/2, where a = width and b = length) Mouse body weight was also recorded. After 14 days of treatment, mice in each group were anesthetized via inhalation of isoflurane and euthanized by cervical dislocation. In subsequent experiments, dissected organs were weighed using an electronic balance, and tumor tissue and major organs were collected for hematoxylin and eosin (H&E) staining and immunocytochemical analysis. Animal Toxicity Assessment Animal Biochemical Analysis: On day 14 following near-infrared photothermal radiation, three groups of mice were anesthetized. Eyeball enucleation was performed to obtain fresh blood samples, preventing hemolysis, followed by euthanasia via decapitation. Blood plasma was collected via low-speed centrifugation (3000 rpm, 10 min) for biochemical testing and stored at −80°C. Organs including heart, liver, spleen, lungs, kidneys, and tumors were dissected and collected. Hematoxylin and eosin (H&E) staining was employed to evaluate the in vivo toxicity of 50-nm CaPHDH particles. All animal experiments were performed in compliance with the guidelines approved by the Ethics Committee of Shanghai Tenth People’s Hospital (SHDSYY-2025-4622). In Vivo Evaluation and Analysis of Immunization Indicators of Macrophage On day 14 following antitumor treatment, mice in each group were euthanized, dissected, and tumor tissue was harvested. A 0.2 g sample of tumor tissue from each mouse was minced and digested with collagenase I and DNase at 37°C for 30 minutes to isolate a single-cell suspension. The digested mixture was filtered through a 70-μm cell strainer to collect the single cells. The cells were then fixed with 4% paraformaldehyde for 30 minutes, and the fixative was removed by centrifugation. The cell pellet was resuspended in 100 μL of flow cytometry staining buffer. First, anti-CD45 antibody was added, and the mixture was incubated at room temperature for 10 minutes; followed by a mixture of anti-F4/80, anti-CD86, and anti-CD206 antibodies (Table S1). After thorough mixing, incubation continued at room temperature for 30 minutes. The cells were washed three times with cell wash buffer, and macrophages in each group of tumor tissues were analyzed using a flow cytometer (BD Fortessa X-20). Data Statistical Analysis All statistical data are reported as mean ± standard deviation, derived from three independent samples per experimental group. Comparisons among multiple groups were performed using one-way analysis of variance (ANOVA), while comparisons between two groups were conducted using Student’s t-test. An asterisk characterizes the existence of significant differences (*P < 0.05, **P < 0.01, ***P < 0.001). Results and Discussion Synthesis and Characterization of CaPHDH To validate the feasibility of the proposed strategy, we employed a green synthetic approach to synthesize in situ sodium hyaluronate (HA)-modified calcium phosphate nanoparticles (CaPHDH) loaded with heme chloride and DOX using Dulbecco’s Modified Eagle Medium (DMEM) as the reaction medium. During this process, by regulating the drug-to-reagent ratio, hemin was incorporated into the crystal lattice during the nucleation and growth stages of calcium phosphate crystals via electrostatic interactions, coordination, or physical entrapment. Subsequently, doxorubicin (DOX) was loaded onto the nanoparticle surface via electrostatic adsorption and further coated with HA to enhance tumor targeting. Transmission electron microscopy (TEM) (Figure 1a) and scanning electron microscopy (SEM) images (Figure 1b) reveal uniform morphology and rough surfaces for the resulting CaPHDH nanoparticles, with an average particle size of approximately 100 nm. CaP NPs are hollow nanoparticles (Figure S1a), and both CaPH (Figure S1b), and CaPHDH (Figure S1c), particles are uniform in size. Dynamic light scattering (DLS) measurements indicate a hydrated particle size of about 150 nm (Figure 1c) and a polydispersity index (PDI) of 0.19, suggesting a narrow particle size distribution. TEM-elemental mapping analysis (Figure 1d and e) further confirmed the spherical structure and uniform elemental distribution of CaPHDH. Fourier transform infrared spectroscopy (FTIR) (Figure 1f) revealed a prominent phosphate characteristic peak at 1030 cm−1 for CaPHH. A peak shift near 1615 cm−1 was observed, likely due to the presence of DOX or interactions with phosphate groups, confirming successful drug loading. In the UV-visible absorption spectrum (Figure 1g), characteristic peaks of heme at approximately 390, 510, and 640 nm, along with the absorption peak of DOX at 480 nm, further confirm the effective loading of both components. Furthermore, the zeta potential of the nanoparticles increased from approximately −17 mV to +18 mV after DOX loading, while HA modification significantly decreased it to about −23 mV (Figure 1h). This change is primarily attributed to the introduction of surface carboxyl groups from HA. Collectively, these results demonstrate the successful preparation of a CaPHDH nanoparticle drug delivery system with well-defined structure, uniform size, and surface functionalization. Characterization of CaPHDH. (a) Transmission electron microscopy (TEM) image and (b) scanning electron microscope (SEM) image of CaPHDH (scale bar =100nm). (c) Particle size distribution of CaPHDH obtained from three independent measurements. (d) EDS elemental mapping of CaPHDH. (e) EDS spectrum of CaPHDH. (f) FT-IR spectrum of CaPHDH. (g) Absorption spectrum in the ultraviolet-visible region of different NPs. (h) Zeta potential of different nanoparticles in aqueous solution. The Photothermal Effect and Drug Release Performance of CaPHDH The synthesized CaPHDH nanoparticles at different concentrations exhibit broad absorption ranges across the ultraviolet to near-infrared wavelength spectrum (Figure 2a), indicating their potential photothermal properties and offering promising prospects for photodynamic therapy applications in tumor treatment. To verify this, we configured nanoparticles at different concentrations for photothermal conversion performance testing. As shown in Figure 2b, this is an infrared thermal image of a microscopic droplet under 808 nm laser illumination. It can be observed that the temperature change in droplets containing CaPHDH is more pronounced than in pure water droplets, indicating that the hemin in CaPHDH exhibit significant absorption of near-infrared light. To further evaluate the photothermal performance of CaPHDH, we irradiated nanoparticle dispersions at different concentrations (0, 0.0625 mg·mL−1, 0.125 mg·mL−1, 0.25 mg·mL−1) with an 808 nm near-infrared laser at varying power densities (2, 3, 4 W·cm−2) for 10 minutes. As shown in Figure 2c, the solution temperature rise rate significantly accelerated with increasing CaPHDH concentration. Similarly, Figure 2d indicates that at the same concentration, higher irradiation power resulted in more pronounced temperature elevation, demonstrating a positive correlation between the photothermal conversion efficiency of CaPHDH and near-infrared laser power. To more intuitively demonstrate its photothermal conversion performance, we employed an infrared thermal imaging camera to record the real-time temperature distribution of CaPHDH at different concentrations under varying laser intensities (Figure 2e). The results were consistent with thermocouple measurements. Furthermore, after three cycles of near-infrared laser irradiation, CaPHDH exhibited excellent photothermal conversion stability (Figure 2f), indicating superior photothermal cycling stability. Characterization of the in vitro photothermal properties. (a) Ultraviolet absorption spectra of nanoparticles of different concentrations. (b) Near-infrared thermal imaging of droplets containing 50μg/mL nanoparticles, and images of ultrapure water droplets with the laser off.(c) Thermal images of samples at different concentrations captured by an infrared camera under 808 nm laser irradiation at varying power levels. (d) Photothermal conversion curves at different concentrations and different powers (e and f) The photothermal conversion curve underwent three cycles. (f) The photothermal conversion curve underwent three cycles. (g) Release of hemin and DOX (h) from CaPHDH nanoparticles in two pH buffer solutions (pH=5.0 or pH=7.4). (i) Hemolysis test. As shown in Figures 2g and h, in a pH 5.0 solution, a significant amount of hemin and DOX were released from the nanoscale system, with a cumulative release rate exceeding 55% within 2 hours. In contrast, only approximately 12% drug release was observed in pH 7.4 PBS buffer. The pronounced pH-responsive release behavior exhibited by CaPHDH lays the foundation for achieving precise drug delivery within the tumor microenvironment. Excellent hemocompatibility is a fundamental requirement for intravenous delivery systems and a key evaluation criterion in biomaterial development.40,41 Hemolysis test results (Figure 2i) indicate that no significant hemolysis occurred upon contact with the prepared nanoparticles. Even at concentrations as high as 250 µg/mL, the hemolysis rate of CaPHDH remained below 5%, indicating excellent blood compatibility and the faint red color of DOX caused minimal interference with the assay (Figure S3). This property can be attributed to the highly hydrophilic hyaluronic acid coating, which not only enhances the dispersion stability of the nanoparticles but also significantly improves their compatibility within the blood environment. Cellular Uptake Behavior and in vitro Cytotoxicity of CaPHDH To investigate the safety design of the nanoreactor and its anti-colon cancer efficacy, we co-cultured CT26 cells with nanoparticles at various concentrations for CCK-8 assays. As shown in Figure 3a, even at a concentration of 250 µg/mL, CT26 cell viability remained above 97% after incubation with Ca NPs indicating Ca NPs exhibit high biocompatibility as nanocarriers. Furthermore,2W of 808nm light irradiation did not enhance CaP NPs’ tumor cell killing capacity, whereas light irradiation significantly reduced tumor cell viability when the nanocarrier was loaded with hemin (Figure 3b), resulting in over 50% cell mortality. Additionally, when loaded with doxorubicin, the viability of the same dose of nanodrug decreased upon light irradiation (Figure 3c). To investigate the cellular uptake behavior of CaPHDH in tumor cells, fluorescence imaging of the nanomedicine within CT26 cells was performed via laser confocal microscopy for various time periods. As shown in fluorescence imaging images (Figure 3d) and fluorescence intensity maps (Figure 3e), after incubation in CT26 cells, the nanoparticles exhibited distinct red DOX fluorescence, and the fluorescence intensity was concentration and time-dependent, confirming their uptake into the cytoplasm of tumor cells. Co-localized green fluorescence from a lysosomal tracer indicated (Figure 3d) that most of the nanomaterials accumulated in lysosomes within 1 hour, and DOX entered the nucleus within 2 hours; the fluorescence was both time and concentration-dependent (Figure S4). The mechanism can be explained as follows: since hyaluronic acid acts as a natural ligand for CD44, CaPHDH is more readily taken up by tumor cells. The confocal imaging results (Figure S5a) and fluorescence intensity statistical analysis (Figure S5b) of CT26 cells and NIH3T3 cells incubated with CaPHDH for 2 hours respectively also proved that CaPHDH is more readily taken up by tumor cells. This colocalization enhances CaPHDH’s responsiveness to acid stimulation, as the acidic environment provided by the lysosomes (pH 4.5–5.5) promotes the release of the loaded DOX and hemin. In vitro cell experiments of NPs. Cell viability experiment. (a) The effects of 808-nm laser and different concentrations of Ca NPs on cell viability; (b) Different concentrations of CaPHH and laser irradiation on cell viability after irradiation; (c) Different concentrations of CaPHDH with light exposure on cell viability. (d) The co-localization of fluorescence images in CT26 cells and the fluorescence intensities of FITC-labeled nanoparticles (red) and lysosomal trackers (green) (scale bar: 20 μm). (e) Fluorescence intensity maps. (f) Effects of different treatment groups on cells and with or without 808nm laser irradiation (Orange arrows), with Calcein/PI staining. Red lines indicate laser irradiation margins. Scale bar: 100 µm. Effects of photothermal therapy on CT26 cells with or without 808 nm laser irradiation (orange arrows). To investigate the cytotoxic effects of nanoreactors on tumor cells, CT26 cells were incubated with nanoparticles of different compositions, and cell viability was assessed using a live/dead cell staining method. As shown in Figure 3f, cells in the PBS-treated control group exhibited only green fluorescence (live cells). The CaPHH-treated group exhibited minimal red fluorescence (dead cells), indicating that this group exerted certain toxic effects on tumor cells by degrading the GPX4 protein. In contrast, the DOX and CaPHDH groups showed significantly enhanced red fluorescence after 808 nm laser irradiation, demonstrating that photothermal effects further amplified the cell killing efficacy. Notably, the CaPHDH group exhibited the strongest red fluorescence upon illumination. This may be attributed to its more efficient cellular uptake, coupled with the synergistic effects of protein degradation, iron-based catalyst activity, and photothermal effects, thereby achieving more effective tumor cell clearance. CaPHDH Induces ROS Production and Protein Degradation in Vitro To evaluate the effect of CaPHDH on tumor cell activity, we subsequently measured the generation of singlet oxygen (1O2) within CT26 cells. As shown in Figure 4a, tumor cells treated with CaHDH and doxorubicin (DOX) exhibited higher reactive oxygen species (ROS) levels than cells treated with CaP NPs nanoparticles alone. When cells were co-incubated with nanoparticles loaded with DOX and hemin, ROS production increased significantly further (Figure 4b). This phenomenon was also validated by flow cytometric analysis. Figure 4c shows that the flow cytometry results were consistent with confocal microscopy observations: the fluorescence intensities in both the DOX group and the CaPHH group were higher than those in the Control group and the CaP NPs group. Among them, the average fluorescence intensity of the CaPHDH group reached 71.8%, approximately equal to the sum of the DOX group (59.3%) and the CaPHH group (18%) (Figure 4d). Under 808 nm laser irradiation, the average fluorescence intensity of CaPHDH co-incubated with cells further increased to 81% (Positive control shows in Figure S6), primarily due to the synergistic effect of DOX and hemin upon photoexcitation. In the acidic tumor microenvironment and under near-infrared laser irradiation, CaPHDH continuously induced high levels of lipid ROS in tumor cells by releasing Fe2⁺ and DOX. Study on the effects of CaPHDH on cells in vitro. (a) Laser confocal microscopy detection of reactive oxygen species (ROS) production within cells following different drug treatments and (b) corresponding analysis results. Scale bar: 20 µm. (c) Flow cytometry analysis of reactive oxygen species (ROS) production in CT26 cells and (d) Corresponding flow cytometry analysis results. (e) Transmission electron microscopy images of mitochondrial morphology in CT26 tumor cells (scale bar = 500 nm) after PBS (e) and CaPHDH (f) treatment for 24 hours. (g) Western blot analysis and statistical analysis of relative gray values of GPX4 (h) and SLC7A11 (i). (j) ATP levels in CT26 cells after incubation with different drugs (control group, CaPNPs, CaPHH, CaPHDH, CaPHDH+L, 50 µg/mL) for 12 hours and 24 hours. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). To investigate the effects of CaPHDH nanomedicine on CT26 cell mitochondria, we examined mitochondrial morphology via transmission electron microscopy and measured ATP production levels using an ATP bioluminescence assay kit. Compared to the control group (Figure 4e), mitochondria in the CaPHDH-treated group (Figure 4f) exhibited marked atrophy, loss of cristae architecture, and increased membrane thickness, indicating that CaPHDH may induce ferroptosis-related mitochondrial structural damage and dysfunction.42,43 Further Western blot analysis assessed the expression levels of ferroptosis-related key proteins GPX4 and SLC7A1144 (Figure 4g–i). Results showed that GPX4 and SLC7A11 protein expression decreased by 42.3±14.03% and 9.45±5.76%, respectively, in the CaPHH group; while GPX4 expression decreased by 51±8.62% and 49.73±6.79% in the CaPHDH and CaPHDH+L (laser irradiation) groups, respectively. SLC7A11 expression significantly decreased by 73.95±19.01% and 76.55±23.9% in these groups, respectively, both higher than in the CaP NPs group. The addition of Fe-1 significantly increased GPX4 protein levels and SCL7A11 expression, thereby inhibiting ferroptosis (Figure S7). In comparison, the combination of CaPHDH+L and Fer-1+CaPHDH+L increased GSH levels by 2.35% ± 0.1% (Figure S8a) and decreased MDA levels by 9.7% ± 3.7% (Figure S8b). These results indicate that the addition of Fer-1 inhibited ferroptosis in the cells. These results indicate that CaPHDH nanodrugs loaded with DOX and hemin can effectively induce ferroptosis in vitro under near-infrared irradiation. As the key site for cellular energy supply, mitochondrial function changes can be reflected by ATP levels. As shown in Figure 4j, ATP levels in CT26 cells treated with CaP NPs for 12 hours reached 96% of the control group, similar to the control (98%); After 24 hours of treatment, ATP levels decreased to 85% of the control group, showing a significant difference compared to the control group (96%). In contrast, ATP levels in cells treated with CaPDH for 24 hours further decreased to 42% of the control group, primarily attributed to hemin and DOX-induced degradation of GPX4 and SLC7A11 proteins. Notably, under near-infrared light irradiation, ATP levels in CaPHDH-treated tumor cells reached the lowest point (approximately 21% of the control group). Over time, the relative ATP levels of CT26 cells in all treatment groups showed a decreasing trend, with stable differences maintained between groups. The Bioavailability and Antitumor Efficacy of CaPHDH in Vivo To evaluate the therapeutic efficacy of the proposed strategy against colon cancer, we established a subcutaneous CT26 cell xenograft mouse model. The specific procedure is shown in Figure 5a: First, CT26 cells (1.5 × 106,100 μL PBS) were injected subcutaneously into BALB/c mice. After 10 days, when tumor volume reached approximately 100 mm3, the tumor-bearing mice were randomly divided into different treatment groups. Subsequently, mice in each group received equal doses (10 mg·kg−1) of PBS, CaP NPs, CaPHH, or CaPDH via tail vein injection every 3 days. During treatment, tumor volume changes were measured and recorded every 2 days to monitor tumor growth. To investigate the in vivo distribution of CaPHDH nanoparticles, we injected free rhodamine-labeled nanoparticles into tumor-bearing mice via the tail vein and collected fluorescence signals at different time points using a small animal in vivo imaging system. As displayed in Figure 5b, the tumor region (delineated by a red dotted circle) showed persistent strong fluorescence signals over the entire observation period, demonstrating efficient accumulation of nanoparticles at the tumor site. This accumulation primarily resulted from passive targeting mediated by the high permeability and retention (EPR) effect in tumor tissues, combined with active targeting via the HA moiety. Furthermore, the persistent strong fluorescence signal at the tumor site 48 hours post-injection suggested that the nanoparticles exhibited prolonged retention in the blood circulation and sustained accumulation within the tumor. To further evaluate distribution specificity, mice were euthanized 48 hours post-administration, and ex vivo fluorescence imaging was performed on tumor tissue and major organs. In vivo imaging results showed that, within 8 hours after injection, the fluorescence signal at the tumor sites in both BALB/c tumor-bearing mice and BALB/c nude mice increased in a time-dependent manner (Figure S9); at 48 hours, the fluorescence intensity in the tumor tissues (delineated by a red dotted circle) of both animal models was significantly higher than that in major organs, confirming that the nanoparticles exhibit good tumor-selective accumulation in both mouse models. (Figures S10 and S11). In vivo bio-distribution and anti-tumor efficacy of CaPHDH. (a) Schematic of tumor development in the colon cancer model and combined humin-DOX therapy. (b) Distribution of CaPHDH nanoparticles in mice at different time points (0 h, 30min, 2 h, 4 h, 8 h, 24 h, 48 h) based on Rh B fluorescence, acquired using a small animal imaging system (tumor tissues were delineated by a red dotted circle). (c) Infrared thermal imaging of animals at different time points under 808-nm laser irradiation. (d) Average tumor growth curves following different treatments. (e) Photographs of tumor tissues after different treatments, (f) Tumor volume analysis across groups after 14 days of treatment and (g) Tumor weights. (h) Body weight records of mice in each treatment group under laser irradiation. (i) Body weight records without laser irradiation. (*p<0.05, **p<0.01, ***p<0.001). Next, we administered the treatment via tail vein injection and monitored the temperature changes at the tumor site of CT26 tumor-bearing mice in real time using an 808 nm infrared thermal imaging system during 10 minutes of near-infrared laser irradiation, 8 hours post-administration. As shown in Figure 5c, with prolonged irradiation duration, the local tumor temperatures in the CaPHDH and CaPHH groups increased significantly, markedly exceeding those in the PBS control group. Corresponding thermographic images (Figure S2) revealed that after 10 minutes of irradiation, the tumor region reached temperatures up to 47°C-sufficient to effectively kill tumor cells during hyperthermia.45,46 In contrast, tumors in the PBS group showed only a slight temperature increase under identical irradiation conditions. This result confirms that hemin exhibits excellent photothermal conversion properties in vivo. To further investigate the antitumor efficacy of CaPHDH, tumor-bearing mice were divided into eight groups: PBS, PBS+laser, CaP NPs, CaP NPs+laser, CaPHH, CaPHH +laser, CaPHDH, and CaPHDH +laser for treatment. As shown in Figure 5d, tumor growth in the CaPHDH +laser group was significantly suppressed during the 14-day monitoring period, with relative tumor volumes substantially lower than the PBS control group. Figures 5e–g further demonstrate that tumor volumes in this group were markedly smaller than those in all other treatment groups. Moreover, compared to the non-irradiated PBS and PBS + laser groups, the CaPHH +laser group also exhibited pronounced tumor growth inhibition. This effect resulted from the synergistic action of the photothermal effect induced by the 808 nm laser and the released Fe2⁺ via the ferroptosis pathway. These findings demonstrate that combining DOX chemotherapy with hemin-mediated photothermal therapy yields superior antitumor efficacy in vivo compared to monotherapy. As shown in Figure 5h and i, no significant differences in body weight were observed among the groups of mice during the 14-day treatment period, indicating that this nanocomposite exhibits good biocompatibility. CaPHDH-Induced Antitumor Immune Responses and Safety Evaluation Given the potent antitumor efficacy of CaPHDH, we hypothesize that this nanomedicine may modulate the tumor immune microenvironment. To investigate the mechanism of CaPHDH in photothermal immunotherapy, we analyzed the infiltration and maturation of antigen-presenting cells—particularly macrophage in mouse tumor tissues. To investigate the mechanism of CaPHDH-induced antitumor immunotherapy, we collected tumor tissues from mice treated with different therapeutic approaches to analyze immune cell infiltration (Figure S3). As shown in Figure 6a and Figure S12, the proportion of mature macrophage (CD11c⁺CD86⁺) among total macrophage significantly differed among treatment groups. The statistical results (Figure S13) of M1 matured in macrophages cells from different groups corresponding to Figure 6a. Both the CaPHDH combined with laser irradiation group (CaPHDH+L) and the CaPHDH monotherapy group markedly promoted macrophage polarization. In contrast, the proportion of mature macrophage in the CaP NPs-treated group showed no significant change. Notably, compared to hemin-mediated photothermal effects alone, hemin combined with DOX appeared to exert a stronger promotion on macrophage in tumor tissues by degrading ferroptosis-related proteins such as GPX4 and SLC7A11. To assess the biological safety of CaPHDH, histopathological analysis was performed on major organs of CT26 tumor-bearing mice. HE staining results (Figure 6b) revealed no significant pathological damage or abnormal changes in major organs including heart, liver, spleen, lungs, and kidneys. Additionally, statistical comparisons of organ weights among all groups (Control, CaP NPs, CaPHDH) (Figure 6c–g) showed no significant differences. Furthermore, serum biochemical analysis indicated that liver function markers (total bilirubin BILT, aspartate aminotransferase AST, alanine aminotransferase ALT) and kidney function markers (uric acid UA, creatinine CREA, urea UREA) remained within normal ranges, with no significant abnormalities observed (Figure 6h and i). The results of the complete blood count analysis (Figure S14) showed that there were no significant differences in the hematological parameters of the CaPHDH group mice compared with the control group (Original data: Tables S2–S10), indicating that this nanosystem has minimal impact on the hematological system of mice and exhibits good in vivo biosafety. In summary, CaPHDH demonstrated favorable biocompatibility in vivo, providing a safety foundation for its potential application in tumor therapy. Analysis of CaPHDH-induced antitumor immune responses and safety evaluation. (a) Flow cytometric analysis of macrophage polarization in tumor tissues. (b) HE-stained histological sections of organs from mice in different treatment groups. (c–g) Analysis of organ weight differences among mice in different treatment groups and analysis of liver function (h) and kidney (i) function in mice from different treatment groups. Conclusions Based on the aforementioned series of studies, we successfully designed and constructed a hemin- and DOX-loaded nanocarrier system, CaPHDH, for colon cancer treatment. This system exhibits remarkable photothermal conversion efficiency, pH-responsive drug release capability, and potent induction of ferroptosis in tumor cells. In vitro experiments demonstrated that CaPHDH effectively heated under near-infrared laser irradiation and specifically released DOX and hemin within acidic tumor microenvironments. The synergistic effects of chemotherapy, photothermal therapy, and ferroptosis significantly enhanced the killing efficacy against CT26 tumor cells. In vivo studies further confirmed CaPHDH’s effective accumulation at tumor sites, where laser irradiation generates sufficient thermal energy. The synergistic release of therapeutic components significantly suppressed tumor growth, demonstrating markedly superior efficacy compared to monotherapies. Biocompatibility assessments revealed excellent safety profiles. Collectively, CaPHDH achieves highly efficient, low-toxicity tumor treatment through intelligent response-driven release and multi-mechanism synergy, offering a promising strategy for developing novel nanomedicine platforms. Acknowledgments This work was supported by the National Clinical Key Specialty Construction Project (grant no. 10000015Z155080000004) and the Shanghai Jiading District Key Discipline Foundation for Medicine (grant no. 2020-jdyxzdxk-06) and the Shanghai Chongming District “Action Plan for Technological Innovation in Sustainable Development” (grant no. CKY2024-47). Data Sharing Statement The data are available from the corresponding author (Bo Zhang and Huanhuan Zhu). Ethics Approval and Consent to Participate This study was approved by the Ethics Committee of Shanghai Tenth People’s Hospital (SHDSYY-2025-4622). Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement The data are available from the corresponding author (Bo Zhang and Huanhuan Zhu).